Life Sciences 13. April 2023 Resistell collaborates with CRISP New collaboration with the Center for Research and Innovation in Clinical Pharmaceutical Sciences (CRISP) at the University Hosptial of Lausanne (CHUV).
Life Sciences 31. March 2023 InSphero announces financing round with ZEISS Ventures InSphero is the global market leader in 3D spheroids and cell-based assays for pharmaceutical drug discovery and safety testing.
Life Sciences 28. March 2023 adivo starts clinical study The Munich based biotech startup announced its first development project entering first-in-patient clinical studies.
Life Sciences 28. March 2023 Thermosome receives BfArM approval Thermosome receives approval to conduct a phase 1 trial with its lead program THE001 in patients with soft tissue sarcoma.
Life Sciences 23. March 2023 Hemotune launches feasibility project with AstraZeneca hemotune initiates a joint feasibility project for its HemoSystem with the renowned pharmaceutical company AstraZeneca.
Life Sciences 23. March 2023 Follow-on investment in Lunaphore OCCIDENT participated in this Series D1 totaling 40 million Swiss francs under the lead of Ernst-Göhner Stiftung Beteiligungen (EGSB).
Life Sciences 19. December 2022 Follow-up Investment in Resistell OCCIDENT has been invested in Resistell since the seed financing and is now again participating in the first tranche of 8.5 million of the Series B.
Industrial Tech 27. September 2022 Initial investment in core sensing OCCIDENT invests in an innovative sensor technology for machine components and takes the lead for the Series A of 4.5M growth capital at core sensing.
Life Sciences 20. September 2022 Initial investment in Avelo OCCIDENT further strengthens its portfolio in the field of diagnostics and leads Avelo’s oversubscribed 2.2 million seed financing round.